Morepen Laboratories gets USFDA clearance for its bulk drug Montelukast Sodium
For sale in US market
Morepen Laboratories announced that USFDA has cleared Montelukast Sodium, a bulk drug/ API manufactured by Morepen Laboratories for sale in the US market. This gives Morepen an entry into the Rs 2000 crore (approx. $300 million) US market for Montelukast. The first commercial order for the bulk drug are expected in Q2 of FY 2018-19.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Dec 20 2017 | 10:23 AM IST